METHOD FOR PREDICTION OF DEVELOPING MYOCARDIAL DYSFUNCTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA Russian patent published in 2013 - IPC G01N33/50 

FIELD: medicine.

SUBSTANCE: invention may be used to predict a developing myocardial dysfunction in the children with acute lymphoblastic leukaemia (ALL) at different stages of polychemotherapy (PCT). That is ensured by a blood examination of an N-terminal fragment of a promoter of brain natriuretic peptide (NT-pro-BNP), a prohormone of atrial natriuretic peptide (pro-ANP), a protein-binding fatty acids (PBFA), ferritin, hepcidin, homocysteine, neopterin before the beginning of PCT and the ferritin 2 level following the remission induction. The derived values of the above parameters are inserted into an equation of ECG, IFM, B(E-Ea), NT-pro-BNP, FB values after the termination of the intensive PCT. A total coefficient K is calculated by the following formula: K=ECG₃×IFM₃×B(E-Ea)₃×NT-pro-BNP₃×FB₃. The coefficient K>0.17 enables predicting the development of cardiac complications.

EFFECT: invention enables choosing the accompanying therapeutic approach for correction and prevention of the myocardial dysfunction in the children with acute lymphoblastic leukaemia.

6 tbl